# Balázs Halmos

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/balazs-halmos/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,393 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 64 |
| i10-index | 176 |
| Last Known Institution | Montefiore Medical Center |
| OpenAlex ID | https://openalex.org/A5081356537 |
| ORCID iD | 0000-0001-7548-8360 |
| Works | 787 |

## Researcher papers

Showing 12 of 14.

- [<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib](https://scholariq.org/papers/i-egfr-i-mutation-and-resistance-of-non-small-cell-lung-cancer-to-gefitinib/)
- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study](https://scholariq.org/papers/clinical-impact-of-covid-19-on-patients-with-cancer-ccc19-a-cohort-study/)
- [Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers](https://scholariq.org/papers/mechanisms-of-acquired-crizotinib-resistance-in-alk-rearranged-lung-cancers/)
- [Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer](https://scholariq.org/papers/activation-of-the-axl-kinase-causes-resistance-to-egfr-targeted-therapy-in-lung/)
- [Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System](https://scholariq.org/papers/case-fatality-rate-of-cancer-patients-with-covid-19-in-a-new-york-hospital/)
- [A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407](https://scholariq.org/papers/a-randomized-placebo-controlled-trial-of-pembrolizumab-plus-chemotherapy-in/)
- [Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib](https://scholariq.org/papers/exon-19-deletion-mutations-of-epidermal-growth-factor-receptor-are-associated/)
- [Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-squamous-non-small-cell-lung-cancer-5-year/)
- [Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations](https://scholariq.org/papers/characterization-of-298-patients-with-lung-cancer-harboring-met-exon-14-skipping/)
- [Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance](https://scholariq.org/papers/combined-vascular-endothelial-growth-factor-receptor-and-epidermal-growth-factor/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Liver physiology and pathology](https://scholariq.org/topics/liver-physiology-and-pathology/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Montefiore Medical Center](https://scholariq.org/institutions/montefiore-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.